Prevalence of BRCA1 and BRCA2 germ line mutations among women with carcinoma of the fallopian tube
Introduction
Fallopian tube cancer is part of the spectrum of cancers in women with a BRCA1 or BRCA2 mutation. This association is based on the reporting of fallopian tube cancers in families known to carry a deleterious BRCA mutation and more recently, due to the finding in several studies of occult fallopian tube cancers at prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 carriers [1], [2], [3], [4], [5], [6], [7]. In 2001, we tested a series of 44 unselected women with fallopian tube cancer and reported that 16% of these patients carried a BRCA1 or BRCA2 mutation [8]. This rate was higher than the 11.7% we found in women diagnosed with invasive serous ovarian cancer [9]. Since 2001, we have expanded our sample of cases from Ontario from 44 to 70, we have added 38 fallopian cancers from Los Angeles and we have screened the entirety of the BRCA1 and BRCA2 genes for mutations in all cases.
Section snippets
Study subjects
The study population of 108 women with fallopian tube cancer is comprised of two separate series. The first series consists of women diagnosed in Ontario from 1990 to 1998 and from 2002 to 2004. The second series consists of women diagnosed with fallopian tube cancer between January 1991 and August 2007 and treated at the Division of Gynecologic Oncology, Department of Obstetrics and Gynecology at Cedars-Sinai Medical Center, Los Angeles, California.
All participants from Ontario were identified
Results
The characteristics of the patients are presented in Table 1. Of the 108 patients with fallopian tube cancer, 33 (30.6%) were found to have a BRCA1 or BRCA2 mutation known to be deleterious; 23 (21.3%) in the BRCA1 gene and 10 (9.3%) in the BRCA2 gene (Table 2).
Family history was positive for 24 (23.3%) of the participants. The mutation prevalence was 58.3% among those 24 women compared to 22.8% among women without a family history. Fourteen (14.4%) of the study participants had a past history
Discussion
Ours is the largest study to date to estimate the proportion of cases of fallopian tube cancer which are due to mutations in the BRCA1 and BRCA2 genes. In our series, we estimate the mutation prevalence to be 30.6%, which is higher than that of unselected breast cancers and ovarian cancers [9], [13], [14]. In 2001, we studied 44 women with fallopian tube cancer, and based on seven mutations, we estimated the prevalence to be 16% [8]. In the present study, we include these 44 original cases and
Conflict of interest statement
There are no conflicts of interest to declare.
References (18)
- et al.
Occult cancer of the fallopian tube in BRCA-1 germline mutation carriers at prophylactic oophorectomy: a case for recommending hysterectomy at surgical prophylaxis
Gynecol Oncol
(2001) - et al.
Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers
Gynecol Oncol
(2006) - et al.
A genetic epidemiological study of carcinoma of the fallopian tube
Gynecol Oncol
(2001) - et al.
Prevalence and penetrance of germline BRCA1 and BRCA2 mutations in a population series of 649 women with ovarian cancer
Am J Hum Genet
(2001) - et al.
An Alu-mediated 6-kb duplication in the BRCA1 gene: a new founder mutation?
Am J Hum Genet
(1999) - et al.
Founder BRCA1 and BRCA2 mutations in French Canadian breast and ovarian cancer families
Am J Hum Genet
(1998) - et al.
Linkage analysis of 26 Canadian breast and breast-ovarian cancer families
Hum Genet
(1995) - et al.
Novel inherited mutations and variable expressivity of BRCA1 alleles, including the founder mutation 185delAG in Ashkenazi Jewish families
Am J Hum Genet
(1995) - et al.
Occult carcinoma in prophylactic oophorectomy specimens: prevalence and association with BRCA germline mutation status
Am J Surg Pathol
(2001)